Data from An Integrative Computational-Experimental Approach Reveals Multi-Target Protective Mechanisms of Xiao-Yao-San against Drug- Induced Liver Injury

Data for cell experimental validation, including Preliminary concentration screening (IC50 and Csafe), APAP-induced HepG2 injury model establishment and cytoprotective effects of compounds, and Comprehensive hepatoprotective efficacy evaluation.Experimental groups included: (1) vehicle control (0.1% DMSO), (2) APAP model group, (3) APAP + beta-sitosterol co-treatment group, (4) APAP + luteolin co-treatment group, (5) APAP + kaempferol co-treatment group, and (6) APAP + quercetin co-treatment group.本数据集用于细胞实验验证，涵盖初步浓度筛选（半数抑制浓度（IC50）与安全浓度（Csafe））、对乙酰氨基酚（APAP）诱导的HepG2细胞损伤模型构建及化合物的细胞保护作用，以及综合性肝保护功效评价。实验分组包括：(1) 溶剂对照组（0.1%二甲基亚砜（DMSO）），(2) APAP模型组，(3) APAP+β-谷甾醇联合给药组，(4) APAP+木犀草素联合给药组，(5) APAP+山奈酚联合给药组，(6) APAP+槲皮素联合给药组。